Isolated limb perfusion based anti-p21ras gene therapy in a rat rhabdomyosarcoma.

BACKGROUND Inhibition of ras oncogene is a promising new strategy. Gene therapy against ras proved successful in human and murine tumour cell lines. Previously we demonstrated effective targeted transfection of tumour in a rat model by using an isolated limb perfusion (ILP) for the delivery of adenoviral vectors. MATERIALS AND METHODS This study explores the anti-tumour activity of an adenoviral construct encoding an intracellular single-chain antibody (scFv) against p21ras (Y28). In order to determine the influence of the ras status on the efficacy of the scFv, we used a wild-type rat rhabdomyosarcoma and its ras-oncogene transfectant, for in vitro studies. In vivo we used the ILP delivery method to study anti-tumour activity on established limb tumours. RESULTS In vitro studies demonstrated an inhibition of growth caused by the Y28 construct. No significant difference between transfected and wild-type cell lines could be demonstrated. Upon ILP, homogeneous transduction was observed in 5% of tumour cells. Perfusion with the Y28 construct, however, did not result in any additional anti-tumour activity compared to controls. CONCLUSION Despite in vitro activity and in vivo transfection, no significant tumour response could be detected using anti-p21ras gene therapy in this ILP-tumour model.

[1]  H-S Liu,et al.  A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  A. Eggermont,et al.  Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion , 2003, British Journal of Cancer.

[3]  A. Eggermont,et al.  Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras , 2002, British Journal of Cancer.

[4]  A. Eggermont,et al.  Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats. , 2001, Human gene therapy.

[5]  A. Eggermont,et al.  Isolated Limb Perfusion for Local Gene Delivery: Efficient and Targeted Adenovirus-Mediated Gene Transfer Into Soft Tissue Sarcomas , 2000, Annals of surgery.

[6]  F. Lang,et al.  Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. , 1999, Cancer research.

[7]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[8]  O. Cochet,et al.  Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific λ and irrelevant κ light chains , 1998 .

[9]  A. Eggermont.  TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. , 1998, Anticancer research.

[10]  O. Cochet,et al.  Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. , 1998, Cancer research.

[11]  B. Feig,et al.  Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[13]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[14]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Ahlering,et al.  Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line. , 1996, The Journal of urology.

[16]  M. Li,et al.  Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. , 1996, Cancer gene therapy.

[17]  A. Eggermont,et al.  Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat , 1996, The British journal of surgery.

[18]  A. Eggermont,et al.  Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  D. Fraker,et al.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Taub,et al.  Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. , 1995, Journal of the National Cancer Institute.

[21]  D. Curiel,et al.  Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. , 1995, Cancer research.

[22]  Hanns Lochmüller,et al.  The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. , 1995, Gene therapy.

[23]  A. W. Boersma,et al.  Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. , 1995, British Journal of Cancer.

[24]  V. A. Flørenes,et al.  Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. , 1994, Cancer research.

[25]  J. Roth,et al.  Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. , 1993, Cancer research.

[26]  J. Pow-Sang,et al.  Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. , 1993, Cancer research.

[27]  P. Bentvelzen,et al.  Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. , 1992, Cancer research.

[28]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Werge,et al.  Intracellular immunization , 1990, FEBS letters.

[30]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[31]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[32]  A. Geiser,et al.  Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. , 1989, Cancer research.

[33]  P Ghazal,et al.  Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Eugenio Santos,et al.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene , 1982, Nature.

[35]  E. Scolnick,et al.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family , 1982, Journal of virology.

[36]  J. Davies,et al.  A new selective agent for eukaryotic cloning vectors. , 1980, The American journal of tropical medicine and hygiene.